Mania in a case of polypsychopharmacology: Pharmacodynamic and pharmacokinetic considerations - Do you believe in magic?

Journal of Psychiatric Practice

Volumn 13, Issue 3, 2007, Pages 178-183

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BUSPIRONE; CARBAMAZEPINE; CLONAZEPAM; FLUOXETINE; HALOPERIDOL; LITHIUM; PAROXETINE; RANITIDINE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; AGGRESSION; AGITATION; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONCENTRATION LOSS; CONFUSION; DISTRESS SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; IRRITABILITY; MANIA; NIGHTMARE; OUTCOME ASSESSMENT; POLYPHARMACY; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; SIDE EFFECT; SLEEP DISORDER; THERAPY EFFECT; TREATMENT RESPONSE; TREMOR;

ADJUSTMENT DISORDERS; ADOLESCENT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BUSPIRONE; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; PAROXETINE; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE, ATTEMPTED;

EID: 34249334639     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000271659.94468.d6     Document Type: Article

References (27)

1. National Center for Health Statistics, Centers for Disease Control. Health, United States, 2004.
2. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9-15.
3. Preskorn SH. Psychopharmacology and psychotherapy: What's the connection? J Psychiatr Pract 2006;12:41-5.
4. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications, Inc.; 1996.
5. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
6. Preskorn SH. If lack of concentration didn't cause the fall, what did? Journal of Practical Psychiatry and Behavioral Health 1996;2:364-7 (Can be accessed at www.preskorn.com/column3.html).
7. Preskorn SH. A tale of two patients. Journal of Practical Psychiatry and Behavioral Health 1999;5:160-4 (Can be accessed at www.preskorn.com/column1. html)
8. Preskorn SH. Duloxetine. J Psychiatr Pract 2004;10:375-85.
9. Sharp T, McQuade R, Bramwell S, et al. Effect of acute and repeated administration of 5-HT1A receptor agonists on 5-HT release in rat brain in vivo. Naunhyn Schmiedebergs Arch Pharmacol 1993;348:339-46.
10. Van den Hooff P, Galvan M. Actions of 5-hydroxytryptamine and 5-HT1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol 1992;106:893-9.
11. Grasby P, Sharp T, Moorman J, et al. Comparison of the effect of buspirone and 1-(2-pyrimidinyl)piperazine on cerebral glucose utilization in the rat. Eur J Pharmacol 1993;230:41-6.
12. Manahan-Vaughan D, Anwyl R, Rowan MJ. The azapirone metabolite 1-(2-pyrimidinyl) piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors. Eur J Pharmacol 1995;294:617-24.
13. Blier P, Curet O, Chaput Y, et al. Tandospirone and its metabolite, 1-(2-pyrimidinyl) piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 1991;39:691-701.
14. Done CJ, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994;33:411-21.
15. Cao BJ, Li WP. Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl) piperazine. Eur J Pharmacol 1994;259:75-8.
16. Martin P. 1-(2-pyrimidinyl)piperazine may alter the effects of the 5-HT1a agonist in the learned helplessness paradigm in rats. Psychopharmacology-Berl 1991;104:275-8.
17. Przegalinski E, Tatarczynska E, Chojnacka-Wojcik E. Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen. Journal of Psychopharmacology 1990;4:204-9.
18. Raghavan N, Zhang D, Zhu M, et al. CYP2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos 2005;33:203-8.
19. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-8.
20. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
21. Bakish D. Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry 1991;36:749-50.
22. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-20.
23. Robillard M, Lieff S. Augmentation of antidepressant therapy by buspirone: Three geriatric case histories. Can J Psychiatry 1995;40:639-40.
24. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
25. Grady TA, Pigott TA, L'Heureux F, et al. Seizure associated with fluoxetine and adjuvant buspirone therapy. J Clin Psychopharmacol 1992;12:70-1.
26. Lebert F, Pasquier F, Goudemand M, et al. Euphoria with buspirone after fluoxetine treatment. Am J Psychiatry 1993;150:167.
27. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.